Teva Earnings Top But Drugmaker’s Sales Just Miss Views

Teva Pharmaceutical (TEVA) on Wednesday reported adjusted earnings of 63 cents per share on $4 billion in sales for its first quarter. In response, Teva stock was little changed.


On average, analysts polled by FactSet expected Teva to earn 59 cents per share on $4.02 billion in sales.

In the year-earlier period, Teva earnings were 76 cents a share and the generic drugs company reported $4.36 billion in sales.

For the year, Teva still sees EPS of $2.50-$2.70. Analysts called for profit of $2.62 a share and $16.7 billion in sales.

In premarket trading on the stock market today, Teva stock rose 0.2%.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Novartis Generics Face ‘Challenging Quarter,’ But Gene Therapy Shines

Eli Lilly Stock Crumbles As Covid Antibodies Hammer Sales, 2021 Outlook

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Get Stock Ideas From IBD Experts Each Morning Before The Open

Watch IBD’s Investing Strategies Show For Actionable Market Insights

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button